Comparative Effectiveness and Safety of Roxadustat versus Erythropoiesis-Stimulating Agents in Patients Receiving Maintenance Hemodialysis: A Real-World Cohort Study
Roxadustat demonstrated superior efficacy in elevating and sustaining Hb levels compared to ESA over a longer observation period, with comparable cardiovascular safety in hemodialysis-dependent CKD patients. Roxadustat represents a viable alternative to ESA for renal anemia management, though long-term multicenter studies are needed to validate safety and optimize clinical use.
Authors
- Zhixi Zhang (ORCID: https://orcid.org/0000-0002-5291-9698)
- Yingxi Kang
- Jing Liu (ORCID: https://orcid.org/0000-0001-8802-0783)
- Ying Liu (ORCID: https://orcid.org/0000-0001-9385-992X)
- Ping Fu (ORCID: https://orcid.org/0000-0003-2963-3402)
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
Publication Details
- Journal
- Kidney Diseases
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1159/000548711
- Citations
- 1
- Primary Topic
- Erythropoietin and Anemia Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.77